Table 2 Association between individual inhaled corticosteroids and adrenal insufficiency.
| ICS exposure before adrenal crisis* | Cases (n = 154) | Controls (n = 870) | OR (95% CI) | OR adjusted for OCS (95% CI)‡ | ||
|---|---|---|---|---|---|---|
| N | % | N | % | |||
| Any inhaled corticosteroid | ||||||
| Never† | 123 | 79.9 | 792 | 91.0 | Reference | Reference |
| >90 days | 9 | 5.8 | 38 | 4.4 | 1.6 (0.7 to 3.4) | 1.0 (0.4 to 2.3) |
| ⩽90 days | 22 | 14.3 | 40 | 4.6 | 3.4 (1.9 to 5.9) | 1.6 (0.8 to 3.2) |
| Fluticasone propionate | ||||||
| >90 days | 1 | 0.6 | 3 | 0.3 | 2.1 (0.2 to 20.6) | 2.6 (0.2 to 28.8) |
| ⩽90 days | 8 | 5.2 | 4 | 0.5 | 10.4 (3.1 to 35.3) | 4.6 (1.3 to 17.0) |
| Budesonide | ||||||
| >90 days | 4 | 2.6 | 14 | 1.6 | 2.0 (0.6 to 6.4) | 1.4 (0.4 to 4.7) |
| ⩽90 days | 1 | 0.6 | 5 | 0.6 | 1.3 (0.2 to 11.5) | Insufficient data |
| Beclometasone dipropionate | ||||||
| >90 days | 12 | 7.8 | 36 | 4.1 | 2.2 (1.1 to 4.3) | 1.1 (0.4 to 2.6) |
| ⩽90 days | 14 | 9.1 | 33 | 3.8 | 2.7 (1.4 to 5.3) | 1.1 (0.5 to 2.7) |
ICS, inhaled corticosteroid; OCS, oral corticosteroid.
*At least one prescription.
†Never exposed to any inhaled corticosteroid (reference for all risk estimates).
‡Adjusted for number of courses of oral corticosteroids per year.